Stealth Biologics
Activity without Immunogenicity.
Immunogenicity constrains the design space available to biologics. The Veil Platform removes limitations, making therapeutics that treat disease without alerting your immune system.
LEAD PROGRAM: Chronic Refractory Gout
Veiled Uricase:
VTX-101
VTX-101 is a uricase-polymer conjugate for the treatment of refractory gout. Over 400,000 refractory gout patients across the world are looking for a new way to treat their disease. VTX-101 seeks to offer relief for these patients.
High-density, short side chains are key for evading immune recognition
The Veil Platform was developed by rearranging the structure of PEG-based polymers into small, discrete units that are significantly less immunogenic. This means that our polymers confer PK extension, stability, and shielding without the immune response. This structural rearrangement adopts a bottlebrush structure, creating a high-density polymer shield near the surface of the protein, where it’s needed most.
The Veil Platform
Delivering drugs hidden
from immune recognition
• Tunable polymer length: 5 to 50 kDa
• Side chain composition controls Tₜ
Validated Applications across:
• Proteins
• Peptides
• Lipid Nanoparticles
• Aptamers
• Depot delivery
We make biologics undetectable,
enabling long-lasting and effective treatments
We move beyond first-gen PEGylation to pioneer the next wave of biologic therapies
Operating Team
-
Ryan // CEO
Ryan Hallett, PhD is a life sciences entrepreneur with expertise in early-stage biologics discovery/development and startup launch. After completing graduate work at UNC-Chapel Hill, Ryan co-founded Dualogics, an antibody development company commercializing the OrthoMab bispecific platform, which was acquired by AbCellera Biologics in 2020. Ryan joined Lanier Biotherapeutics in 2021 as VP of Product Development and led R&D efforts to develop an IL-25 antibody for the treatment of Pneumonitis. In 2025, Ryan joined Veil Therapeutics as CEO, bringing the company out of stealth to develop its lead program.
-
Angus // Founder
Dr. Angus Hucknall is a seasoned scientist and entrepreneur with a proven track record in clinical diagnostics and polymer science. He has co-founded three companies and is a co-inventor of the PEGNEXT technology utilized by Veil Therapeutics. With over 30 publications and 10 patents to his name, Angus brings a wealth of expertise to the company. He earned his MS in Materials Science and Engineering from MIT and his PhD in Biomedical Engineering from Duke University.
-
Soumen // CSO
Dr. Soumen Saha holds a PhD in Chemical Science with a specialization in drug delivery, brings over a decade of experience in the research and development of advanced macromolecular therapeutics. His work has provided deep expertise in the synthesis of complex macromolecules and a strong understanding of formulation stability and biological performance. Dr. Saha’s technical skills align closely with the experimental and strategic requirements of this project. He will play a central role in designing, managing, and analyzing key studies necessary to move the technology toward clinical development.
-
Tosh // Chairman, Founder
Dr. Ashutosh Chilkoti is the Alan L. Kaganov Distinguished Professor of Biomedical Engineering at Duke University, where he leads a research group dedicated to developing biomolecular materials for applications such as bio-separations, biosensors, biomaterials, and targeted drug delivery. A distinguished academic and serial entrepreneur, Dr. Chilkoti has authored over 400 publications and holds more than 70 patents. As the founder of multiple startup companies, he excels at translating groundbreaking academic research into innovative commercial products.